Kolon TissueGene
Blood & Organ Banks · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9713 Ave Key West Ste 300, Rockville, Ma...Phone Number
(301) 921-6000Website
www.tissuegene.comRevenue
$7.5 MillionIndustry
ZI Rank: 5
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
3
3
7
5
5
About Kolon TissueGene
Kolon TissueGene, Inc., is an advanced cell therapies company that has developed a first-in-class cell and gene therapy targeting OA of the knee. Kolon TissueGene's lead product, TG-C, is an allogeneic cell and gene therapy. The Company has plans for two pivotal Phase III clinical trials in knee OA in the U.S., the first under a Special Protocol Assessment (SPA) agreement reached with the U.S. Food and Drug Administration (FDA).Explore more
Kolon TissueGene Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kolon TissueGene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Kolon TissueGene launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Kolon TissueGene has new funding data
Check out if Kolon TissueGene is spiking on competitors!
Check if Kolon TissueGene has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Kolon TissueGene
Click to see if Kolon TissueGene had a recent Job posting/layoffs
Earning: See what the market has to say on Kolon TissueGene recently announced quarterly report
Kolon TissueGene, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Kolon TissueGene
Compare insights from companies similar to Kolon TissueGene, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$5.2M
11-50
Private
<$5M
2013
TN
Tushar NuwalBusiness Corporate Development, Alliance Management & Commercial Strategy Head
Company Profile Activity
Activity Insights
Kolon TissueGene is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Kolon TissueGene is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Kolon TissueGene.
Kolon TissueGene financials insights
Gather financial insights about Kolon TissueGene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Other Financing Round
$29.6M
Kolon TissueGene Tech Stack
A closer look at the technologies used by Kolon TissueGene
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Funding
Project
Information Security
Kolon TissueGene News & Media
KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY FOR TG-C AT OARSI WORLD CONGRESS
THE WORLD'S MOST PRESTIGIOUS OSTEOARTHRITIS SOCIETY (OARSI) HELD FOR THE FIRST TIME IN KOREA LONG-TERM SAFETY DATA FROM OVER 15 YEARS SUPPORT THE SAFETY PROFILE OF TG-C, WITH PRELIMINARY SIGNS OF POTENTIAL EFFICACY BENEFITS ROCKVILLE, Md., April 28, 2025 /PRNewswire/ -- Kolon TissueGene...KOLON TISSUEGENE COMPLETES PATIENT DOSING IN TWO PIVOTAL US PHASE III CLINICAL TRIALS FOR TG-C
Completed patient dosing in US Phase 3 clinical trials. There will be a two-year follow-up period, followed by submission of the Biologics License Application (BLA) to permit marketing of TG-C once approved. ROCKVILLE, Md., July 11, 2024 /PRNewswire/ -- Kolon TissueGene, Inc. ('the...KOLON TISSUEGENE RESUMES TG-C PHASE III STUDIES IN THE U.S.
ROCKVILLE, Md., Dec. 28, 2021 /PRNewswire/ -- Kolon TissueGene, Inc. (KOSDAQ: 950160) (the "Company"), a leader in advanced cell and gene therapies, announced today that it has resumed patient dosing in its U.S. Phase III study of TG-C for the treatment of knee osteoarthritis (OA). The...Kolon TissueGene To Expand Indications For TG-C
ROCKVILLE, Md., Dec. 3, 2021 /PRNewswire/ -- Kolon TissueGene, Inc. ("the Company"), a leader in advanced cell and gene therapies, announced today that the FDA has allowed the Company to proceed with initiation of a Phase II clinical trial in osteoarthritis (OA) of the hip. Kolon...
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kolon TissueGene
Sign Up For FreeTo access detailed company insights
Kolon TissueGene, Inc., is an advanced cell therapies company that has developed a first-in-class cell and gene therapy targeting OA of the knee. Kolon TissueGene's lead product, TG-C, is an allogeneic cell and gene therapy. The Company has plans for two pivotal Phase III clinical trials in knee OA in the U.S., the first under a Special Protocol As... Read More
